Common use of Press Releases and Other Permitted Disclosures Clause in Contracts

Press Releases and Other Permitted Disclosures. (a) MacroGenics and BI each agree not to disclose any terms and conditions of this Agreement to any Third Party, except as described below in this Section 8.4. The press release announcing the collaboration contemplated by this Agreement is set forth in Schedule 8.4, and the Parties will cooperate in the release thereof as soon as practicable after the Effective Date. Subject to the other provisions of this Agreement, no other press release, public statement or disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval shall not be unreasonably withheld or delayed *** following submission to the approving Party of a draft of the respective press release, public statement or disclosure. In no event shall such subsequent press releases, public statements or disclosures by MacroGenics disclose, if previously undisclosed, ***; provided that MacroGenics may disclose the receipt of any milestone event but not the actual amount of such milestone payment under this Agreement. Once any public statement or disclosure has been approved in accordance with this Section 8.4, then either Party may appropriately communicate information contained in such permitted statement or disclosure. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.

Press Releases and Other Permitted Disclosures. (a) MacroGenics Licensor and BI Licensee each agree not to disclose any of the terms and conditions of this Agreement to any Third Party, except as described below in this Section 8.48.5 or as otherwise agreed in writing by the Parties. The Parties have agreed on a press release announcing the collaboration contemplated by this Agreement is in substantially the form set forth in Schedule 8.4Exhibit E, together with a corresponding Question & Answer outline for use in responding to inquiries about the Agreement. The initial press release will be issued in a mutually agreed time and the Parties will cooperate in the release thereof as soon as practicable manner after the Effective DateDate and thereafter, each Party may disclose to Third Parties the information contained in such press release and Question & Answer outline without the need for further approval by the other Party. Subject Each Party may also desire to issue subsequent press releases or other public statements relating to this Agreement or activities hereunder. The Parties agree to consult with each other reasonably and in good faith with respect to the text of such press releases or other provisions of this Agreement, no other press release, public statement or disclosure concerning disclosures and obtain the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval shall not be unreasonably withheld or delayed *** following submission prior to the approving issuance thereof; provided, however, that a Party of a draft of the respective press release, public statement may not unreasonably withhold or disclosure. In no event shall delay consent to such subsequent press releases, public statements or disclosures by MacroGenics disclose, if previously undisclosed, ***; provided that MacroGenics may disclose the receipt of any milestone event but not the actual amount of such milestone payment under this Agreement. Once any public statement or public disclosure has been approved in accordance with this Section 8.48.5, then either Party may appropriately communicate the information contained in such permitted statement or disclosure. *** = Portions of For clarity, to the extent a public disclosure is required by applicable Law, this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the CommissionSection 8.5(a) shall not apply, and such disclosure shall instead be governed by Section 8.5(d) below.

Press Releases and Other Permitted Disclosures. (a) MacroGenics Cara and BI Vifor each agree not to disclose any of the terms and conditions of this Agreement to any Third Party, except as described below in this Section 8.48.3. The Parties will cooperate in the release of a mutually agreed upon press release release, within thirty (30) days following execution of the Agreement, announcing the collaboration contemplated by this Agreement is set forth in Schedule 8.4, and the Parties will cooperate in the release thereof as soon as practicable after the Effective Date. Subject to the other provisions of this Agreement, no other press release, public statement or public disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval shall not to be unreasonably withheld or delayed *** following submission withheld; provided, however, the foregoing limitation does not apply to the approving Party of extent a draft of the respective press release, public statement or disclosurepublic disclosure contains information that was previously disclosed publicly. In no event shall such subsequent press releases​ CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, public statements or disclosures by MacroGenics disclose, if previously undisclosed, MARKED BY [***; provided that MacroGenics may disclose the receipt of any milestone event but not the actual amount of such milestone payment under this Agreement], HAS BEEN OMITTED BECAUSE CARA THERAPEUTICS, INC. Once any public statement or disclosure has been approved in accordance with this Section 8.4HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CARA THERAPEUTICS, then either Party may appropriately communicate information contained in such permitted statement or disclosureINC. *** = Portions of this exhibit have been omitted pursuant to a request for confidential treatmentIF PUBLICLY DISCLOSED. An unredacted version of this exhibit has been filed separately with the Commission.​